Prophylactic Human Vaccine Market
Because of the enormous number of
government research funds, North America is likely to lead the worldwide
prophylactic human vaccination market. For example, the U.S. Army
Medical Research Acquisition Activity awarded GeoVax Labs, Inc., a U.S.-based
company, a grant of $2,442,307 in September 2018. The grant was given as part
of a cooperative agreement for the development of a novel Lassa Fever (LF) vaccine
(GEO-LM01). GEO-LM01 employs a vaccine platform based on Modified Vaccinia
Ankara (MVA) and Virus-Like Particle (VLP) that has been shown to be safe and
generate antibody responses in patients.
Read More:
https://knackersblogger.blogspot.com/2022/09/prophylactic-human-vaccine-market-size.html
